Mitral valve surgery in heart failure: Insights from the Acorn Clinical Trial

Michael A. Acker, Steven Bolling, Richard Shemin, James Kirklin, Jae Kuen Oh, Douglas L. Mann, Mariell Jessup, Hani N. Sabbah, Randall C. Starling, Spencer H. Kubo

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Objective: The study objective was to evaluate in a prospective, randomized, multicenter trial the safety and efficacy of mitral valve surgery with and without the CorCap cardiac support device (Acorn Cardiovascular, St Paul, Minn) in patients with New York Heart Association Class II to IV heart failure. Background: Although mitral valve surgery has been performed successfully in patients with heart failure, the safety and long-term efficacy have not been established in a multicenter prospective trial. Cardiac support devices that reduce ventricular wall stress and promote beneficial reverse remodeling have been proposed as a new treatment option as a stand-alone procedure and as an adjunct to mitral valve surgery. Methods: A subgroup of 193 patients were enrolled in the mitral valve repair or replacement stratum of the Acorn Clinical Trial; 102 patients were randomized to the mitral valve surgery alone group (control) and 91 patients were randomized to mitral valve surgery with implantation of the CorCap cardiac support device. Patients were followed for a median duration of 22.9 months. Results: For the entire mitral valve surgery group, the 30-day operative mortality rate was only 1.6% at 30 days. Mitral surgery was associated with progressive reductions in left ventricle end-diastolic volume, left ventricle end-systolic volume, and left ventricular mass, and increases in left ventricle ejection fraction and sphericity index, all consistent with reverse remodeling. Recurrence of clinically significant mitral regurgitation was uncommon. Quality of life, exercise performance, and New York Heart Association functional class were all improved. Finally, the addition of the CorCap cardiac support device led to greater decreases in left ventricular end-diastolic volume and left ventricular end-systolic volume, a more elliptical shape, and a trend for a reduction in major cardiac procedures and improvement in quality of life compared with mitral surgery alone. Conclusions: These findings suggest that there is clear benefit to the surgical elimination of mitral regurgitation and that there is additional benefit with the CorCap cardiac support device. Given the improvement in left ventricle structure and function, along with a low mortality rate, physicians should strongly consider offering mitral valve surgery in combination with the CorCap cardiac support device to patients with heart failure who are on an optimal medical regimen.

Original languageEnglish (US)
JournalJournal of Thoracic and Cardiovascular Surgery
Volume132
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Mitral Valve
Heart Failure
Clinical Trials
Equipment and Supplies
Heart Ventricles
Stroke Volume
Mitral Valve Insufficiency
Multicenter Studies
Quality of Life
Safety
Mortality
Exercise
Physicians
Recurrence
Control Groups

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Mitral valve surgery in heart failure : Insights from the Acorn Clinical Trial. / Acker, Michael A.; Bolling, Steven; Shemin, Richard; Kirklin, James; Oh, Jae Kuen; Mann, Douglas L.; Jessup, Mariell; Sabbah, Hani N.; Starling, Randall C.; Kubo, Spencer H.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 132, No. 3, 09.2006.

Research output: Contribution to journalArticle

Acker, MA, Bolling, S, Shemin, R, Kirklin, J, Oh, JK, Mann, DL, Jessup, M, Sabbah, HN, Starling, RC & Kubo, SH 2006, 'Mitral valve surgery in heart failure: Insights from the Acorn Clinical Trial', Journal of Thoracic and Cardiovascular Surgery, vol. 132, no. 3. https://doi.org/10.1016/j.jtcvs.2006.02.062
Acker, Michael A. ; Bolling, Steven ; Shemin, Richard ; Kirklin, James ; Oh, Jae Kuen ; Mann, Douglas L. ; Jessup, Mariell ; Sabbah, Hani N. ; Starling, Randall C. ; Kubo, Spencer H. / Mitral valve surgery in heart failure : Insights from the Acorn Clinical Trial. In: Journal of Thoracic and Cardiovascular Surgery. 2006 ; Vol. 132, No. 3.
@article{b25a9d3798b74793ba99acf67aa53bae,
title = "Mitral valve surgery in heart failure: Insights from the Acorn Clinical Trial",
abstract = "Objective: The study objective was to evaluate in a prospective, randomized, multicenter trial the safety and efficacy of mitral valve surgery with and without the CorCap cardiac support device (Acorn Cardiovascular, St Paul, Minn) in patients with New York Heart Association Class II to IV heart failure. Background: Although mitral valve surgery has been performed successfully in patients with heart failure, the safety and long-term efficacy have not been established in a multicenter prospective trial. Cardiac support devices that reduce ventricular wall stress and promote beneficial reverse remodeling have been proposed as a new treatment option as a stand-alone procedure and as an adjunct to mitral valve surgery. Methods: A subgroup of 193 patients were enrolled in the mitral valve repair or replacement stratum of the Acorn Clinical Trial; 102 patients were randomized to the mitral valve surgery alone group (control) and 91 patients were randomized to mitral valve surgery with implantation of the CorCap cardiac support device. Patients were followed for a median duration of 22.9 months. Results: For the entire mitral valve surgery group, the 30-day operative mortality rate was only 1.6{\%} at 30 days. Mitral surgery was associated with progressive reductions in left ventricle end-diastolic volume, left ventricle end-systolic volume, and left ventricular mass, and increases in left ventricle ejection fraction and sphericity index, all consistent with reverse remodeling. Recurrence of clinically significant mitral regurgitation was uncommon. Quality of life, exercise performance, and New York Heart Association functional class were all improved. Finally, the addition of the CorCap cardiac support device led to greater decreases in left ventricular end-diastolic volume and left ventricular end-systolic volume, a more elliptical shape, and a trend for a reduction in major cardiac procedures and improvement in quality of life compared with mitral surgery alone. Conclusions: These findings suggest that there is clear benefit to the surgical elimination of mitral regurgitation and that there is additional benefit with the CorCap cardiac support device. Given the improvement in left ventricle structure and function, along with a low mortality rate, physicians should strongly consider offering mitral valve surgery in combination with the CorCap cardiac support device to patients with heart failure who are on an optimal medical regimen.",
author = "Acker, {Michael A.} and Steven Bolling and Richard Shemin and James Kirklin and Oh, {Jae Kuen} and Mann, {Douglas L.} and Mariell Jessup and Sabbah, {Hani N.} and Starling, {Randall C.} and Kubo, {Spencer H.}",
year = "2006",
month = "9",
doi = "10.1016/j.jtcvs.2006.02.062",
language = "English (US)",
volume = "132",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Mitral valve surgery in heart failure

T2 - Insights from the Acorn Clinical Trial

AU - Acker, Michael A.

AU - Bolling, Steven

AU - Shemin, Richard

AU - Kirklin, James

AU - Oh, Jae Kuen

AU - Mann, Douglas L.

AU - Jessup, Mariell

AU - Sabbah, Hani N.

AU - Starling, Randall C.

AU - Kubo, Spencer H.

PY - 2006/9

Y1 - 2006/9

N2 - Objective: The study objective was to evaluate in a prospective, randomized, multicenter trial the safety and efficacy of mitral valve surgery with and without the CorCap cardiac support device (Acorn Cardiovascular, St Paul, Minn) in patients with New York Heart Association Class II to IV heart failure. Background: Although mitral valve surgery has been performed successfully in patients with heart failure, the safety and long-term efficacy have not been established in a multicenter prospective trial. Cardiac support devices that reduce ventricular wall stress and promote beneficial reverse remodeling have been proposed as a new treatment option as a stand-alone procedure and as an adjunct to mitral valve surgery. Methods: A subgroup of 193 patients were enrolled in the mitral valve repair or replacement stratum of the Acorn Clinical Trial; 102 patients were randomized to the mitral valve surgery alone group (control) and 91 patients were randomized to mitral valve surgery with implantation of the CorCap cardiac support device. Patients were followed for a median duration of 22.9 months. Results: For the entire mitral valve surgery group, the 30-day operative mortality rate was only 1.6% at 30 days. Mitral surgery was associated with progressive reductions in left ventricle end-diastolic volume, left ventricle end-systolic volume, and left ventricular mass, and increases in left ventricle ejection fraction and sphericity index, all consistent with reverse remodeling. Recurrence of clinically significant mitral regurgitation was uncommon. Quality of life, exercise performance, and New York Heart Association functional class were all improved. Finally, the addition of the CorCap cardiac support device led to greater decreases in left ventricular end-diastolic volume and left ventricular end-systolic volume, a more elliptical shape, and a trend for a reduction in major cardiac procedures and improvement in quality of life compared with mitral surgery alone. Conclusions: These findings suggest that there is clear benefit to the surgical elimination of mitral regurgitation and that there is additional benefit with the CorCap cardiac support device. Given the improvement in left ventricle structure and function, along with a low mortality rate, physicians should strongly consider offering mitral valve surgery in combination with the CorCap cardiac support device to patients with heart failure who are on an optimal medical regimen.

AB - Objective: The study objective was to evaluate in a prospective, randomized, multicenter trial the safety and efficacy of mitral valve surgery with and without the CorCap cardiac support device (Acorn Cardiovascular, St Paul, Minn) in patients with New York Heart Association Class II to IV heart failure. Background: Although mitral valve surgery has been performed successfully in patients with heart failure, the safety and long-term efficacy have not been established in a multicenter prospective trial. Cardiac support devices that reduce ventricular wall stress and promote beneficial reverse remodeling have been proposed as a new treatment option as a stand-alone procedure and as an adjunct to mitral valve surgery. Methods: A subgroup of 193 patients were enrolled in the mitral valve repair or replacement stratum of the Acorn Clinical Trial; 102 patients were randomized to the mitral valve surgery alone group (control) and 91 patients were randomized to mitral valve surgery with implantation of the CorCap cardiac support device. Patients were followed for a median duration of 22.9 months. Results: For the entire mitral valve surgery group, the 30-day operative mortality rate was only 1.6% at 30 days. Mitral surgery was associated with progressive reductions in left ventricle end-diastolic volume, left ventricle end-systolic volume, and left ventricular mass, and increases in left ventricle ejection fraction and sphericity index, all consistent with reverse remodeling. Recurrence of clinically significant mitral regurgitation was uncommon. Quality of life, exercise performance, and New York Heart Association functional class were all improved. Finally, the addition of the CorCap cardiac support device led to greater decreases in left ventricular end-diastolic volume and left ventricular end-systolic volume, a more elliptical shape, and a trend for a reduction in major cardiac procedures and improvement in quality of life compared with mitral surgery alone. Conclusions: These findings suggest that there is clear benefit to the surgical elimination of mitral regurgitation and that there is additional benefit with the CorCap cardiac support device. Given the improvement in left ventricle structure and function, along with a low mortality rate, physicians should strongly consider offering mitral valve surgery in combination with the CorCap cardiac support device to patients with heart failure who are on an optimal medical regimen.

UR - http://www.scopus.com/inward/record.url?scp=33747763725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747763725&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2006.02.062

DO - 10.1016/j.jtcvs.2006.02.062

M3 - Article

C2 - 16935112

AN - SCOPUS:33747763725

VL - 132

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 3

ER -